by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
by Tyler Wenzel | Dec 21, 2023
I can recall the first time that I heard about the idea of gene therapy. It was over 20 years ago, and possibly like many students in school, I was assigned to write an essay on the ethical considerations for allowing or disallowing gene editing on humans. I remember...
by Stacey Johnson | Dec 1, 2023
Do you remember the column “Life, Interrupted” by cancer patient Suleika Jaouad? She was 22 when she was diagnosed with acute myeloid leukemia (AML) and a rare blood disorder called myelodysplastic syndrome. With her hopes to be a war correspondent on hold (dashed?),...
by Tyler Wenzel | Nov 23, 2023
Cell therapies that replenish a healthy cell niche have long been an attractive approach to treat a variety of diseases, such as Parkinson’s disease, which are incurable and characterized by the loss of critical cell functions. The attractiveness of cell therapies is...
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
by Stacey Johnson | Oct 13, 2023
Blue Rodeo is an iconic Canadian band that performs “countrified rock” and has been around for four decades. It has received multiple awards and accolades, including being inducted into the Canadian Music Hall of Fame, and lead singers/songwriters Jim Cuddy and Greg...
Comments